Pharmaceuticals Overview
Hauptman Ham provides sophisticated intellectual property counsel to pharmaceutical innovators developing life-changing therapies and diagnostic solutions. Our Pharmaceuticals team combines legal acumen with deep technical experience to support clients across the drug development lifecycle—from early-stage research through commercialization and market exclusivity strategies.
We represent clients working at the forefront of therapeutic innovation, including antibodies and immunology, peptides, biologics, biosimilars, and vaccines. Our team also supports technologies related to personalized medicine, stem cells and regenerative medicine, and diagnostic tools that are transforming how diseases are detected and treated.
Our attorneys include professionals with advanced degrees in molecular biology, chemistry, pharmacology, and biotechnology, giving us the scientific fluency to understand complex inventions and navigate regulatory frameworks, such as those governed by the FDA, EMA, and global biosimilar approval pathways.
We assist with patent prosecution, portfolio development, freedom-to-operate analyses, trade secret protection, and strategic licensing. We also advise on patent term extensions, Orange Book listings, and exclusivity strategies under Hatch-Waxman and the Biologics Price Competition and Innovation Act (BPCIA).
In addition, we work closely with clients developing critical pharmaceutical research tools and reagents, as well as companies involved in the biological manufacturing of chemicals and therapeutic compounds.
Whether protecting a breakthrough therapeutic or defending a market position in the face of biosimilar entry, Hauptman Ham delivers IP strategies that support innovation, investment, and impact in the highly competitive pharmaceutical landscape.